NEW YORK--(BUSINESS WIRE)--Radformation, Inc., a leader in automation solutions for cancer care, announced today that it has acquired privately-held Limbus AI, a leading global provider of automated contouring software for radiation therapy. This acquisition signifies Radformation’s commitment to driving innovation and expanding its AI-driven capabilities in cancer care. “Our mission has always been to improve the radiation therapy process, focusing on efficiency, quality, and safety in patient care,” said Kurt Sysock, CEO of Radformation. “With Limbus' innovative technology and expertise now part of our team, we are even more equipped to advance the frontier of innovative software solutions in radiation therapy.”. This merger aims to harness the collective strengths of both companies' platforms by integrating the superior features of each system, offering the most advanced AI-driven contouring solution available today. Beyond improving contouring, this effort is expected to spark further innovation, leading to new developments and improvements in radiation therapy

NOVA YORK--(BUSINESS WIRE)--Radformation, líder em soluções de software clínico e operacional para tratamento do câncer, anunciou hoje que recebeu autorizações regulatórias para suas soluções de automação de radioterapia* da Therapeutic Goods Administration (TGA) na Austrália, da Agência Nacional de Vigilância Sanitária (ANVISA) no Brasil, da Health Canada no Canadá e da Administração de Alimentos e Medicamentos (FDA) na Tailândia. “Essas autorizações refletem nosso compromisso com a inovação global em saúde e nossa dedicação em atender aos rigorosos padrões regulatórios essenciais para melhorar o atendimento aos pacientes no mundo inteiro”, disse Kurt Sysock, CEO da Radformation. Incluído nessas autorizações está o AutoContour, a solução de segmentação e perfilamento automática baseada em IA da Radformation, projetado para iniciar o processo de planejamento do tratamento. Em um estudo de caso recente, o AutoContour demonstrou diminuir o tempo de planejamento do perfilamento em uma média de 84% em todos os locais anatômicos, gerando perfilamentos altamente precisos, levando a uma melhor consistência do plano de tratamento. Os primeiros usuários brasileiros do AutoContour e do ClearCheck, o software automatizado de verificação de plano secundário da Radformation, a Liga Catarinense de Combate ao Câncer - Radioterapia São Sebastião e o Real Hospital Português de Beneficência, selecionaram as ferramentas da Radformation para complementar suas crescentes modalidades de tratamento de última geração e expandir a carga de pacientes

NEW YORK--(BUSINESS WIRE)--Radformation, a leader in clinical and operational software solutions for cancer care, announced today that it has received regulatory clearances for its radiotherapy automation solutions* from the Therapeutic Goods Administration (TGA) in Australia, the National Health Surveillance Agency (ANVISA) in Brazil, Health Canada and the Thai Food and Drug Administration (FDA). “These clearances reflect our commitment to global healthcare innovation and our dedication to meet the rigorous regulatory standards essential to improve patient care worldwide” said Kurt Sysock, CEO of Radformation. Included in these clearances is AutoContour, Radformation’s AI-driven auto-segmentation and contouring solution designed to jump start the treatment planning process. In a recent case study, AutoContour was shown to decrease contour planning time by an average of 84% across all anatomical sites, generate highly accurate contours, leading to improved treatment plan consistency. Early Brazilian adopters of AutoContour and ClearCheck, Radformation’s automated secondary plan check software, Liga Catarinense de Combate ao Câncer - Radioterapia São Sebastião and Real Hospital Português de Beneficência selected Radformation’s tools to complement their growing state of the art treatment modalities and expanding patient load